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Abstract
Objective: To assess the early vascular effects of sunitinib in patients with renal cell carcinoma (RCC) with diffusion-
weighted magnetic resonance imaging (DWI), dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI)
and T2* perfusion MRI. Patients and methods: In 10 patients with abdominal RCC lesions, DWI, DCE-MRI and T2*
perfusion MRI measurements at 3 Tesla were performed at baseline, 3 and 10 days after start of sunitinib. VEGF-A
plasma levels were measured on days 0, 3 and 10. Results: DWI showed a significant increase in the apparent
diffusion coefficient (106 s/mm2) from baseline (mean 1158, range 8142003) to day 3 (mean 1306, range
10082097, P¼ 0.015) followed by a decrease to baseline levels at day 10 (mean 1132, range 7192005,
P¼ 0.001). No significant changes were found in mean DCE-MRI parameters. T2* perfusion MRI showed a signif-
icant decrease in relative tumor blood volume (rBV) and relative tumor blood flow (rBF) at day 3 (rBV P¼ 0.037, rBF
P¼ 0.018) and day 10 (rBV P¼ 0.006, rBF P¼ 0.009). VEGF-A plasma levels significantly increased after 10 days,
but did not correlate with MRI parameters. Conclusions: Sunitinib induces antiangiogenic effects as measured by DWI
and T2*-perfusion MRI, 3 and 10 days after the start of the initial treatment. DCE-MRI did not show significant
changes. In the near future, early functional MRI-based evaluation can play an important role in tailoring treatment to
the individual patient with RCC. Further investigation is warranted.
Keywords: Sunitinib; renal cell carcinoma; dynamic contrast-enhanced magnetic resonance imaging; diffusion-weighted magnetic
resonance imaging; T2* perfusion magnetic resonance imaging.
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Introduction
Angiogenesis is essential for the growth and metastases
of tumors. Several angiogenesis inhibitors are registered
for the treatment of metastatic renal cell carcinoma
(mRCC), including sunitinib[1,2]. There is a great need
to predict clinical outcome early after the start of suniti-
nib treatment in order to optimize treatment schedules
and prevent unnecessary toxicity and costs. Size changes
as assessed by computed tomography (CT) scans accord-
ing to the Response Evaluation Criteria for Solid Tumors
(RECIST) guidelines[3] cannot be expected in this early
phase. Therefore, new predictive and reliable biomarkers,
are needed[4].
Several functional magnetic resonance imaging (MRI)
techniques are attractive as early predictors of response
to sunitinib treatment. Dynamic contrast-enhanced MRI
(DCE-MRI) is a noninvasive functional imaging tech-
nique that can be used to measure the properties of the
tumor microvasculature in vivo. T1 sequences sensitive to
the presence of contrast medium in the extravascular
extracellular space (EES) can provide information on
microvessel perfusion, permeability, and extracellular
leakage space[5]. Diffusion-weighted MRI (DWI) pro-
vides information about the random (Brownian) motion
of water molecules. The movement of water molecules in
the extracellular space is modified by interactions with
cell membranes and macromolecules. Therefore, DWI
can be used to monitor cellularity and necrosis. Informa-
tion about tumor blood volume and tumor blood flow
can be obtained with T2*-perfusion MRI after a second
administration of contrast. This is based on the assump-
tion that the first bolus of contrast saturated the
EES[6].This pilot study aims to assess the early vascular
changes in RCC lesions induced by sunitinib using DCE-
MRI, DWI and T2* perfusion MRI at 3 Tesla.
Methods
Patients
Ten patients with RCC planned for sunitinib treatment
who had progressive RCC lesions of at least 2 cm in
diameter in the liver, kidneys, abdominal lymph nodes
or intra-abdominal soft tissue were included. Both the
50mg once daily 4 weeks on/2 weeks off schedule as
well as the 37.5mg once daily continuously schedule
were accepted. Exclusion criteria were comparable with
the usual exclusion criteria for contrast MRI, including a
glomerular filtration rate530ml/min/1.73m2. Prior sys-
temic treatment including other tyrosine kinase inhibitors
(TKIs) was allowed provided that it had been stopped
because of progressive disease at least 2 weeks before
study entry. CT response evaluation was performed
every 2 cycles of treatment according to RECIST. The
results of the functional imaging techniques measured on
day 0, 3 and 10 of the first cycle, were compared with the
RECIST evaluation after the first 12 weeks of treatment
(2 cycles). This RECIST evaluation and the functional
imaging analyses were performed by the same observer.
All patients gave written informed consent. The study
was approved by the medical ethical committee.
DWI, DCE-MRI and T2*-perfusion
MRI data acquisition
DWI, DCE-MRI and perfusion MRI were performed at
baseline, and at 3 and 10 days after the start of the first
sunitinib treatment cycle. These time points were chosen
based on the hypothesis of time-dependent changes in
tumor vascularization during treatment with angiogenesis
inhibitors, starting with normalization of the vasculature
and ending with loss of vasculature and necrosis[7].
Measurements were performed on a 3.0-T Siemens
Magnetom Trio MR system (Siemens, Erlangen,
Germany), using body phased array receive coils. After
conventional T1- and T2-weighted imaging, echo-planar
DWI was obtained during 22-s breath holds after maxi-
mal expiration, using 3 gradient factors (b¼ 50, b¼ 300
and b¼ 600 s/mm2). This was repeated 3 times in exactly
the same way. Sequence parameters were: resolution time
1800ms, echo time 62ms, field of view 360 317mm,
matrix 100 88, 13 slices of 10-mm thickness, fat sup-
pression and parallel factor 2.
Proton density weighted images were acquired with the
same sequence parameters as the DCE-MRI except for a
flip angle of 10 and repetition time (TR) 250ms. DCE-
MRI was performed after administration of 15ml of 0.5
M gadolinium (Gd)-DOTA (Dotarem, Schering, Berlin,
Germany) intravenously (iv) in 6 s by a SpectrisTM MR
injection system. Using a two-dimensional T1-weighted
fast low-angle shot (FLASH) gradient echo sequence
with a time resolution of 2 s, Gd-DOTA uptake in
the tissue was monitored during 5min. A vascular nor-
malization function (VNF) was determined from pixels
in the spleen[8,9]. Sequence parameters were: TR 39ms,
echo time (TE) 2.08ms, a 45, field of view 350 
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After the dynamic T1 measurements, a second bolus of
15ml of 0.5 M Gd-DOTA was administered iv in 3.75 s
followed by dynamic T2* weighted echo-planar measure-
ments during 90 s in order to measure perfusion[10].
Sequence parameters were: TR 1000ms, TE 23ms, a
90, field of view 320 180mm, 4 slices of 10mm.
For follow-up scans, slice positions were matched with
the first session using anatomic hallmarks as a reference.
Data analysis
DWI
To improve the DWI resultsm DWI measurements were
repeated 3 times at each time point. At a tumor level that
was adequately imaged at all 9 occasions, a two-dimen-
sional region of interest (ROI) was drawn to include the
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whole tumor and regions of presumed necrosis.At every
time point, for each tumor level, a mean apparent diffu-
sion coefficient (ADC) map was calculated out of the 3
DWI sequences made at that specific time point. These
mean ADC maps were compared for days 0, 3 and 10.
ADCs were calculated using Inline diffusion software
(Siemens Syngo VB15). All ROIs, including those for
DCE-MRI and T2*-perfusion MRI, were drawn by the
same observer. Mean ADC map outcomes were averaged
for each time point.
DCE-MRI
DCE-MRI data were analyzed according to the pharma-
cokinetic model and consensus nomenclature essentially
as proposed by Tofts et al. were used[22]. These include:
(1) a volume transfer constant Ktrans (per minute), (2)
the volume of the EES per unit volume of tissue e, and
(3) the flux rate constant between EES and plasma kep
(per minute). The rate constant is the ratio of the transfer
constant to the EES (kep¼Ktrans/e). Lower values of kep
or Ktrans can indicate (1) lower perfusion, (2) lower per-
meability and/or (3) a smaller blood vessel surface area,
globally denoting reduced tumor vascularity[22]. By com-
bining data from the proton density images with the
DCE-MRI data, the tissue concentration of Gd-DOTA
was estimated[23]. The relaxivity of Gd-DOTA was
assumed to be homogeneously distributed. The spatial
distribution of the values of the rate constant kep and
volume transfer constant Ktrans were represented in a
map. ROIs were drawn around all tumor tissue on a
T1-weighted MR image, recorded directly before the
arrival of Gd-DOTA in the tumor. These ROIs were
applied to the maps of kep and K
trans in order to select
the single values of kep and K
trans for all tumor pixels. The
means of kep and K
trans of the pixels of all slices contain-
ing tumor tissue were calculated after log transformation.
All pixels with values equal to zero were regarded as
fitting errors or necrotic tumor parts and were excluded.
Back transformation of this log-transformed average
value resulted in an average value of kep and K
trans for
the whole tumor[19]. Histograms of the log-transformed
values of kep and K
trans were analyzed as described
before[24,25]. This histogram analysis does not assess
changes in mean kep or K
trans values within a tumor
ROI, but calculates a low threshold value (TVlow) from
the formula [TV¼M&minus;1.96 SD] and a high
TV from the formula [TVhigh¼Mþ 1.96 SD] for kep
and Ktrans, where M and SD are the mean and the stan-
dard deviation values at baseline. After treatment, the
number of pixels below TVlow and above TVhigh were
compared with baseline. This method provides more
information about the heterogeneity within a tumor,
which is necessary because tumors may have a necrotic
part or a balance in immature and more mature
neovasculature.
T2*-perfusion MRI
The T2*-perfusion images were analyzed using the stan-
dard Siemens Syngo VB15 software. ROIs were drawn
around RCC lesions. Relative tumor blood volume (rBV)
(AU) and tumor blood flow (rBF) (AU/s) were deter-
mined, enabling the calculation of the mean transit time
(MTT) (s) as: MTT¼ rBV/rBF[15,16].
Vascular endothelial growth factor
A (VEGF-A)
Baseline and 3 and 10 days after starting sunitinib, blood
samples were taken to analyze for VEGF-A. Plasma sam-
ples were stored at &minus;80C within 1 h after veni-
puncture. Plasma concentrations were measured with the
four-antibody sandwich ELISA[17]. Data were correlated
to the MRI parameters.
Statistics
To analyze the change in MRI and blood biomarkers
within the 3 time moments, 2-tailed paired t tests were
performed on log-transformed values. Log transformation
was used because of the limited number of patients.
Correlations were determined using the Pearson correla-
tion test and 95% regression and prediction intervals were
calculated using SPSS (ver. 16.0). A P value50.05 was
considered significant. Data on correlations with progres-
sion-free survival (PFS) are provided but this study is not
powered to reveal the ability of the techniques to predict
PFS and should therefore be interpreted cautiously.
Results
Patients
For this pilot study we aimed to include 10 patients with
RCC with adequate DWI and DCE-MRI measurements
at all 3 time points. Optimization of T2*-perfusion
MRI sequences was finalized after the first patients
had already started and were therefore available for 8
patients. The baseline characteristics of the 10 patients
treated with sunitinib are reported in Table 1. The
median PFS was 22 weeks (mean 37 weeks, range
5115 weeks). Prior cytokine or TKI treatment did not
influence the PFS or functional MRI results (P40.1).
DWI
The mean ADC increased significantly from baseline
(1158 106 s/mm2, range 8142003) to day 3
(1306 106mm2/s, range 10082097) (P¼ 0.015)
followed by a significant decrease on day 10
(1132 106mm2/s, range 7192005) (P¼ 0.010)
(Figs. 1 and 2). Neither baseline ADC values nor the
change in ADC values were correlated with dynamic
T1 and T2* results, or with RECIST results (P40.1).
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DCE-MRI
No significant differences were observed in the mean
values for kep and K
trans (P40.1) (Fig. 1). No correlation
was found between the change in kep and K
trans values
and response according to RECIST after 2 cycles of treat-
ment. The histogram analyses revealed no significant
changes. The decrease in mean kep and K
trans values
after 10 days of sunitinib treatment correlated with pro-
longed PFS (kep, r¼0.598 and P¼ 0.052; Ktrans,
r¼0.617, P¼ 0.043.
T2* perfusion MRI
The mean rBV significantly decreased from baseline
(1019.8 AU, range 412.11944.0) to day 3 (721.0 AU,
range 55.81996.7) (P¼ 0.044) and between baseline
and day 10 (573.5 AU, range 99.71597.6) (P¼ 0.007)
(Fig. 3a). The mean rBF was significantly lower on day
10 (69.2 AU/s, range 12.4148.1) compared with base-
line (154.3 AU/s, range 83.3290.8) (P¼ 0.002)
(Fig. 3b). We observed a decrease in mean MTT from
baseline (9.15 s, range 1.517.6) to day 3 (6.8 s, range
11.5) (P¼ 0.015) but not from baseline to day 10 (11.5 s,
range 4.018.4) (P40.1) (Fig. 3c). Baseline rBV values
were correlated with PFS (r¼ 0.836, P¼ 0.010), as did
rBV values at days 3 and 10 (r¼ 0.736, P¼ 0.037;
r¼ 0.0751, P¼ 0.032, respectively). Baseline rBF and
day 10 rBF values also correlated with PFS (r¼ 0.739,
P¼ 0.036 and r¼ 0.904, P¼ 0.002) (Fig. 5). The change
in rBV or rBF did not correlate with PFS or with
RECIST response after 2 cycles of treatment (all
P40.1).
VEGF-A
Mean VEGF-A plasma levels increased significantly from
baseline (0.74 ng/ml) to day 3 (0.89 ng/ml) (P¼ 0.049)
and between baseline and day 10 (1.41 ng/ml)
(P¼ 0.010). VEGF levels were not correlated with
DWI, DCE-MRI or perfusion MRI results or with PFS.
Discussion
This is the first study to use 3 functional MRI techniques
to assess the early vascular changes in RCC patients
induced by sunitinib. As early as 3 days after start of
sunitinib, we observed significant increases in ADC,
rBV and rBF. In 2010, early response after 15 days of
sunitinib treatment in patients with metastatic RCC was
observed by dynamic contrast-enhanced ultrasonogra-
phy[18]. Furthermore, fluorodeoxyglucose (FDG)-posi-
tron emission tomography (PET)/CT has been
successfully used to assess the effects of 23 cycles of
sunitinib treatment in patients with RCC[19,20].
DWI is able to provide information about cellularity,
edema and necrosis. We observed a significant increase
of ADC values in RCC lesions after 3 days of sunitinib.
This may be caused by the development of necrosis, cell
swelling and edema. For chemotherapy, increases in
ADC have been reported within days due to cell death
with a subsequent increase in extracellular space[21.22].
We found a subsequent decrease of ADC maps back to
baseline values at day 10. This decrease at day 10 com-
pared with day 3 could be explained by tissue
Table 1 Baseline patient characteristics (n¼ 10)
Characteristic
Age (years)






Prior treatment, n (%)
Cytokines 2 (20)
Prior TKI 3 (30)
Tumor types, n (%)
Clear cell carcinoma 8 (80)
Papillary carcinoma 1 (10)
Mixed clear cell/papillary carcinoma 1 (10)
Median tumor diameter, cm (range) 8.1 (2.327.8)
Liver (%) 5 (50)
Kidney (%)
Lymph node (%) 3 (30)
Abdominal fat mass (%) 2 (20)
Sunitinib dose, n (%) 2 (20)
50mg (4/2 schedule) 8 (80)
37.5mg (continuous dose) 2 (20)
Figure 1 DWI shows a significant increase of ADC
(\106mm2/s) from baseline (mean 1158, range
8142003) to day 3 (mean 1306, range 10082097,
P¼ 0.015) followed by a decrease to baseline levels at
day 10 (mean 1132, range 7192005, P¼ 0.001).
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dehydration following cell death and by ischemia as a
result of decreased blood flow, which was observed by
perfusion MRI[23,24]. A decrease in ADC maps was also
noted 24 weeks after the start of sorafenib treatment in
patients with hepatocellular carcinoma (HCC)[24]. In
that study, treatment-related intralesional hemorrhage
was suggested as an explanation for the decrease in
ADC. We have no data about changes in ADC after
day 10. In the HCC trial, an increase in ADC maps
was observed after 23 months of sorafenib treatment.
Such a re-increase could be explained in cases of sus-
tained cell necrosis leading to enlargement of the extra-
cellular space and thus a loss of diffusion restriction.
Only 4 other clinical DWI studies with targeted therapies
have been performed previously. In 2 studies the effect of
bevacizumab, a monoclonal antibody against VEGF, was
assessed. A trend toward an increase in mean ADC
values was observed in patients with brain tumors who
did not have progression after 1 year of treatment[25]. In
the second study on patients with glioblastoma multi-
forme (GBM), lower baseline ADC values were asso-
ciated with a more favorable outcome after 6 months
of treatment[26]. In a third study, the effect of the anti-
vascular drug combrestatin A4 phosphate alone as well
as the combination of combrestatin A4 phosphate and
bevacizumab was studied in patients with solid tumors. A
significant increase in median ADC was observed 3 h
after the second administration of combrestatin A4 phos-
phate, which decreased after the administration of beva-
cizumab[27]. In the last study, tumor escape of GBM
during treatment with cediranib, a VEGF-receptor inhib-
itor, was associated with an increase in low ADC areas,
which represented growing tumor with increasing
cellularity[28].
In this small pilot study, we did not find significant
changes in DCE-MRI parameters after 310 days of
treatment with sunitinib. We did find some correlations
with PFS but in these very small numbers, this should be
interpreted with caution. In 2 previous studies, decreases
in DCE-MRI parameters after 412 weeks of treatment
with sorafenib in RCC have been reported[29,30]. In one
of these studies, high baseline Ktrans was associated with
better treatment outcome and the change in Ktrans corre-
lated with the PFS[30]. Studies with DCE-MRI and
sunitinib have not been performed in patients with
RCC before. The vascular effects of sunitinib have
been assessed by DCE-MRI in a phase II study
in patients with recurrent or metastatic squamous
Figure 2 Change in ADC over time. (A) Large tumor in the left kidney visualized by conventional T1 MRI. (B)
Baseline ADC map projected on conventional T1 MRI image. Mean ADC value 814\ 106mm2/s. (C) Increase in
ADC values after 3 days of treatment with sunitinib. Mean ADC value 1239\ 106mm2/s. (D) Recovery to baseline
ADC values 10 days after starting sunitinib. Mean ADC value 719\ 106mm2/s.
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cell carcinoma of the head and neck, and a significant
decrease in Ktrans was observed after 68 weeks in 3 out
of 4 patients[31]. In HCC patients treated with sunitinib,
significant decreases in kep and K
trans were observed after
14 days, which were more pronounced in responding
patients[32].
Extracranial T2*-perfusion MRI is relatively new. We
observed a decrease in rBV and rBF after 3 and 10 days
of sunitinib treatment. One could speculate that high
baseline rBV and rBF values are determined by high
intratumoral VEGF concentrations and may thus be
related to treatment response to VEGFR inhibitors.
These tumors will be more vulnerable to treatment mod-
alities interfering with the VEGF pathway. The increase
in VEGF plasma levels during antiangiogenic treatment
is well known and does not reflect intratumoral VEGF
levels[33]. Indeed, we did not find a correlation between
VEGF-A plasma levels and functional MRI parameters.
However, the values of rBV and rBF as early biomarkers
of response to antiangiogenic treatment in cancer
patients are still to be determined.
Besides functional MRI, molecular imaging techniques
can be of interest in patients with mRCC treated with
TKIs. For example, Kayani et al. reported that baseline
FDG-PET/CT yields prognostically significant data in
patients with mRCC treated with sunitinib. FDG-PET/
CT responses were visible in most patients after 4 weeks
of therapy. However, it took 16 weeks for the response to
become prognostically significant[34]. Earlier response
evaluation with molecular imaging techniques have not
yet been published.
In conclusion, functional MR imaging provides prom-
ising biomarkers for treatment response. The 3 functional
MRI techniques used in this study provided additional
information and can be applied in one scan session. This
is important for optimal tailoring of personalized thera-
pies in the future. We performed a pilot study in a small
and relatively heterogeneous study population including
patients pretreated with TKIs and the relationship with
PFS has still to be determined. Therefore, further inves-
tigation is needed.
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